Other drugs may affect Buprenex, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed here. Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed. Every effort has been made to ensure that the information provided by Cerner Multum, Inc. Drug information contained herein may be time sensitive.
Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise.
Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient.
Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
This information does not replace the advice of a doctor. Healthwise, Incorporated, disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. Learn how we develop our content. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated. Updated visitor guidelines.
You are here Home » buprenorphine injection - Buprenex. Top of the page. What is the most important information I should know about Buprenex? What is buprenorphine? Buprenex is an opioid medicine used to treat moderate to severe pain. Buprenex may also be used for purposes not listed in this medication guide.
What should I discuss with my healthcare provider before using Buprenex? You should not use Buprenex if you are allergic to buprenorphine, or if you have:. How should I use Buprenex? Introduction of new formulations internationally requires more qualitative studies to inform safer practices.
Keywords: buprenorphine-naloxone; harm reduction; intravenous drug abuse; patient non-adherence; qualitative research. Abstract Introduction and aims: Experiences of buprenorphine-naloxone BNX sublingual film injection are not well documented or understood. Publication types Research Support, Non-U. One patient discontinued treatment with Suboxone during the 4-week study period due to adverse events, and 5 patients discontinued due to adverse events during the follow-up period.
There were no deaths or other serious adverse events reported for patients in the study. There was no apparent relationship between the average Suboxone daily dose taken during the 4-week study period and the reporting of adverse events.
The study has several limitations. Due to the retrospective nature of the study, there were no control groups and the results are only descriptive. However, the patient data were used to assess any general trends associated with the switch to Suboxone, which may provide an insight into the best clinical practices for using Suboxone as a replacement for Subutex.
A survival analysis of the client characteristics and history regarding the time to drop out could have been interesting. Given the relatively small sample size and the scope of this study, however, this sample may not have sufficient power to detect any but the strongest patterns. Satisfaction and compliance differed significantly amongst the treatment centers, thus site specific issues might account for findings also.
The main aim of this study was to follow the medication dose and adverse events during a transfer from buprenorphine to buprenorphine-naloxone combination. The possible dose adjustments were decided by the doctors and were based on each individual's weaning, withdrawal symptoms and adverse events. However, only one patient discontinued Suboxone due to adverse events or dissatisfaction, and one patient left the treatment program retention rate of This indicates that the side effects at this point probably might not predict patients' likelihood of staying in treatment.
Indeed, patient records indicate that many of the reported adverse events were interpreted as being the result of anxiety about being forced to switch to Suboxone. However, it is notable that during 4 month follow up period only It should be noted anxiety interpretation is more of a speculation than measured assessment.
Interestingly, over half of the patients still on Suboxone during the 4 month follow up asked for a dose reduction of Suboxone. This may indicate that the adverse events could be related to higher buprenorphine serum levels, because buprenorphine in Suboxone has slightly higher sublingual bioavailability than the buprenorphine in Subutex [ 6 ].
The dose reductions of Suboxone were mainly done during the follow-up period which may indicate that bioavailability of high dose of Suboxone in the long term should be more thoroughly investigated. It should be noted, however, that the earlier Australian study [ 5 ] had found a need for a dose increase, rather than a decrease, when switching from buprenorphine to the combination medication, that could be related to the "low" 12 mg average dose of Suboxone in that study.
During the follow-up period relative high number of patients Most of them were either transferred to methadone The most common reason for methadone transfer generally in Finland is polydrug abuse. It is possible that psychiatric distress, when patients did not feel confident with the forced transfer from Subutex to Suboxone, may lead to "illegally top-up" with Subutex, that in turn could lead to medication change to methadone. It is possible also, that because the high illicit use of buprenorphine in Finland [ 5 ], the treating personnel had a mistrust on patients reports of Suboxone adverse events, and instead of chancing back to Subutex patients were changed to methadone.
Thus, the "forced" transfer event could be a unique situation in Finland and may not be present elsewhere i. Switching from Subutex to Suboxone did not increase abuse of other opioids. Based on the retrospective nature and small numbers in the study, no solid conclusions about Suboxone diversion can be done. However, interestingly during the follow-up period of the 60 opioid dependent patients, only 5 patients attempted to misuse Suboxone. Furthermore, they reported that while they tried to inject Suboxone, they would not repeat the experience, suggesting that the transfer to Suboxone may also serve as part of an overall strategy to curb misuse of buprenorphine.
In conclusion, a transfer from Subutex to Suboxone should be carefully discussed and planned in advance with the patients and after the transfer adverse events should be regularly monitored.
With regard to buprenorphine abuse, the combination product seems to have a more favorable safety profile than treatment with buprenorphine alone. The results of this study suggest that in high dose Suboxone treatment, dose adjustments should be considered, especially in the later phase of the treatment, if patients report an unusually high number of adverse events.
Also based on the clinical data gathered it is recommended that transfers should be discussed and planned in advance with the patients to minimize psychiatric distress and lack of compliance leading to lower retention rates. Psychopharmacology Berl. Drug Alcohol Depend. Drug Alcohol Rev. Article PubMed Google Scholar. Download references. We thank the data collecting physicians Drs.
You can also search for this author in PubMed Google Scholar. Correspondence to Hannu Alho. Reprints and Permissions. Simojoki, K. Subst Abuse Treat Prev Policy 3, 16 Download citation. Received : 27 September Accepted : 17 June Published : 17 June Anyone you share the following link with will be able to read this content:.
Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Skip to main content.
0コメント